Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: August 10, 2009
Last updated: December 23, 2014
Last verified: December 2014

This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.

Condition Intervention Phase
Ovarian Cancer
Basal Cell Carcinoma
Metastatic Colorectal Cancer
Drug: Vismodegib
Drug: Bevacizumab
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Percentage of Participants Who Experienced at Least 1 Adverse Event [ Time Frame: Baseline until 30 days following the last administration of study treatment ] [ Designated as safety issue: No ]
  • Percentage of Participants Who Discontinued Treatment Due to an Adverse Event [ Time Frame: Baseline until 30 days following the last administration of study treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incidence and Severity of All Adverse Events and Serious Adverse Events [ Time Frame: 30 days following the last administration of study treatment ] [ Designated as safety issue: No ]
  • Incidence of Adverse Events Leading to GDC-0449 Discontinuation [ Time Frame: 30 days following the last administration of study treatment ] [ Designated as safety issue: No ]

Enrollment: 19
Study Start Date: September 2009
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vismodegib 150 mg
Participants received 150 mg vismodegib orally once a day until disease progression, intolerable toxicity, or withdrawal from the study. If a participant had been receiving combination chemotherapy and/or biotherapy (FOLFOX, FOLFIRI, bevacizumab) in a parent study, the same combination chemotherapy and/or biotherapy as specified in the parent study could be continued in this study at the discretion of the investigator.
Drug: Vismodegib
Vismodegib was supplied in capsules.
Other Names:
  • Erivedge
  • GDC-0449
  • RO5450815
FOLFOX (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and oxaliplatin [OX]) was supplied as solutions for intravenous administration.
FOLFIRI (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and irinotecan [IRI]) was supplied as solutions for intravenous administration.
Drug: Bevacizumab
Bevacizumab was supplied as a solution for intravenous administration.
Other Name: Avastin


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

This study only enrolled participants who took part in previous studies of vismodegib conducted by Genentech.

Inclusion Criteria:

  • Completed vismodegib treatment within 2-4 weeks in a Genentech-sponsored parent study or continued to receive vismodegib at the time the Genentech-sponsored parent study closed.
  • Expectation by the investigator that the participant may continue to benefit from additional vismodegib treatment.

Exclusion Criteria:

  • Intervening anti-tumor therapy not specified in the parent study (ie, non-protocol-specified chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00959647

United States, Arizona
Scottsdale, Arizona, United States, 85258
United States, California
Oakland, California, United States, 94609
Palm Springs, California, United States, 92262
Stanford, California, United States, 94305
United States, Maryland
Baltimore, Maryland, United States, 21231
United States, Michigan
Ann Arbor, Michigan, United States, 48109-0934
Detroit, Michigan, United States, 48201
United States, Nevada
Las Vegas, Nevada, United States, 89106
United States, Ohio
Cincinnati, Ohio, United States, 45242
United States, Texas
Houston, Texas, United States, 77030
Sponsors and Collaborators
Genentech, Inc.
Study Director: Josina Reddy, MD, PhD Genentech, Inc.
  More Information

No publications provided

Responsible Party: Genentech, Inc. Identifier: NCT00959647     History of Changes
Other Study ID Numbers: SHH4437g, GO01352
Study First Received: August 10, 2009
Results First Received: December 23, 2014
Last Updated: December 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Genentech, Inc.:
Hedgehog pathway inhibitor processed this record on March 03, 2015